Sorrento Therapeutics, Inc. announced that Kevin M. Herde has been appointed to the position of Executive Vice President & Chief Financial Officer. Mr. Herde joins Sorrento with a proven track record of success and over 20 years of progressive experience in finance, accounting, and general management roles. Most recently he was the Vice President of Global Blood Screening and Alliance Management for Hologic, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0113 USD | -22.07% | +7.62% | -90.85% |
Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-90.85% | 6.14M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.61% | 21.96B | |
-9.33% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Sorrento Therapeutics, Inc. Appoints Kevin M. Herde as Executive Vice President & Chief Financial Officer